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Abstract 
Rationale:The effecicacy of rehabilitation therapy for aphasia caused by stroke is uncertain.  
 
Aims and Hypothesis: The Very Early Rehabilitation of Speech (VERSE) trial aims to determine if 
intensive prescribed aphasia therapy (VERSE) is more effective and cost saving than non-
prescribed, intensive (Usual Care-Plus) and non-intensive usual care (UC) therapy when started 
within 15 days of stroke onset and continued daily over four weeks. We hypothesise that 
aphasia therapy when started very early after stroke and delivered daily could enhance 
recovery of communication compared with usual care. 
 
Sample size estimates: 246 participants (82 per arm) will provide 80% power to detect a 4.4% 
improvement on AQ between VERSE and UC plus at a significance level of α = 0.05. 
 
Methods and design: Setting: Acute-care hospitals and accompanying rehabilitation services 
throughout Australia, 2014-2017. 
Design: Prospective, randomised, paralell group, open-label, blinded endpoint assessment 
(PROBE) trial. 
Participants: acute stroke in previous 14 days and aphasia diagnosed by Aphasia Quotient (AQ) 
of the Western Aphasia Battery (WAB). 
Randomisation: Computer-generated blocked and stratified randomisation procedure by 
aphasia severity according to WAB, to one of three arms. 
Intervention: All participants receive Usual care (UC) - usual ward based aphasia therapy. Arms 
2 and 3 receive a total of twenty additional sessions (45-60 minutes, provided daily) of aphasia 
therapy. Arm 1: Usual Care (UC) - (no additional therapy); Arm 2: UC-Plus usual ward based 
therapy; Arm 3:  VERSE therapy - a prescribed and structured aphasia therapy program. The 
additional intervention must be provided before day 50 post stroke.  
Study outcome measures: the AQ of WAB at 12 weeks post-stroke. Secondary outcomes include 
discourse measures, the Stroke and Aphasia Quality of Life  Scale-39 (SAQoL-39) and the 
Aphasia Depression Rating Scale (ADRS) at 12 and 26 weeks. Economic evaluation: Incremental 
cost-effectiveness ratios at 26 weeks will be reported. 
 
Discussion: This trial is designed to test whether the intensive and prescribed VERSE 
intervention is effective in promoting maximum recovery and preventing costly health 
complications in a vulnerable population of survivorsof stroke. It will also provide novel, 
prospective, aphasia specific cost-effectiveness data to guide future policy development for this 
population. 
  
  
Introduction and Rationale 
Aphasia affects approximately a third of the 440,000 individuals living with stroke in Australia 
[1]. Recovery from aphasia is highly variable with multiple factors believed to contribute to the 
overall extent of communication recovery achieved by each individual[2]. There are currently 
few available specific medical treatments designed to reduce the impacts of aphasia occurring 
as a consequence of stroke, therefore aphasia rehabilitation is the mainstay of recovery for 
people with aphasia.   
 
Early aphasia rehabilitation is thought to enhance the natural processes of spontaneous 
recovery by strengthening neural networks through the use of highly repetitious, task-specific 
behaviours that require coinciding neuronal firing of a group of connected neurons[3]. These 
behaviours are believed to minimise independent neuronal activation that may produce 
maladaptive behaviours[3]. 
 
The 2012 Cochrane Review examined 39 trials of aphasia therapy following stroke and found no 
Level 1 evidence[4] for the efficacy of aphasia treatments in the long-term. There was some 
evidence that speech and language therapy (SLT) was more effective than no SLT however 
caution is required when interpreting the Cochrane Review[4] results as many studies were 
comparative in nature, lacked adherence to the CONSORT statement[5] and demonstrated 
inferior design quality[4]. Additionally, little is known about the costs of available treatment 
options.  
 
Aims and Hypotheses 
VERSE aims to determine if intensive aphasia therapy provides greater efficacy and is at least 
cost-effective when compared to usual ward based rehabilitation (UC) at 12 weeks post stroke, 
when therapy is commenced within the first fifteen days post stroke. Aphasia therapy in this 
trial refers to direct impairment-based aphasia treatment in contrast to other communication 
therapy, case-management, patient/family counselling and education. 
Our primary hypothesis is that compared to UC, early intensive aphasia therapy will result in 
improved communication ability, determined by at least a 20% greater score on the (AQ) of the 
(WAB)[6] at 12 weeks post stroke.  
Secondary hypotheses: 
i) VERSE aphasia therapy will result in a 4.4% greater score on the AQ when compared to 
UC-Plus aphasia therapy at 12 and 26 weeks post stroke. 
ii) Very early intensive aphasia therapy will result in better quality of life using SAQol – 39 at 
12 and 26 weeks post stroke than UC control.  
iii) Very early intensive aphasia therapy will be more cost-effective than UC at 26 weeks 
post stroke.  
VERSE is a three-armed prospective, single-blinded multicentre, randomised controlled trial 
with primary outcome 12 weeks and follow-up at 26 weeks post-stroke (see Figure 1) and 
intention to treat analysis.  
 
Patient Population 
 Approximately 16 acute care hospitals and related rehabilitation services in Australia and New 
Zealand will be involved. Participants include acute stroke patients (>18 years) with aphasia (AQ 
score <93.7) who are otherwise medically stable, who provide consent, and are assessed and 
randomised by the baseline assessor within 14 days of stroke. See Table 1 for inclusion and 
exclusion criteria. 
Methods 
The intervention is provided by qualified and trained speech pathologists for a maximum of 25 
working days, commencing the day after baseline assessment and randomisation (see Figure 2). 
Participants and families in addition to staff not involved in providing the intervention to 
participants are blinded to group allocation.  
Randomisation 
Participants are stratified by baseline aphasia severity, (AQ scores mild: 62.6 – 93.7, Moderate: 
31.3 – 62.5 and severe: 0 – 31.2) and then randomised to one of three groups. The 
randomisation schedule was created by an independent statistician, using a computer-
generated permuted blocked procedure and allocation ratio of 1:1:1. Participants are 
randomise via a web based electronic data collection system. (REDCapTM)[7]. 
Intervention 
ARM 1: Usual Care (UC)  
Participants will receive usual care alone. UC speech pathologists will be responsible for all 
speech pathology services including case management, education, counselling and any co-
occurring dysphagia management for all trial participants. We have anticipated the intensity of 
UC direct aphasia therapy to be less than 6 hours in total based on our previous work [6,8].  
 
ARM 2: Usual Care – Plus (UC-Plus)  
In addition to usual care, the UC-Plus group will receive aphasia therapy that is determined by 
the treating therapist; at the prescribed regimen: 
(a) between 45-60 minutes of 1:1 therapy 5 days per week for 20 sessions (15-20 hours) (within 
a maximum of 25 working days)  
(b) a minimum of 3 and a maximum of 5 sessions per week  
 
ARM 3: VERSE Therapy 
The VERSE aphasia therapy intensity and timing of commencement of intervention will match 
the UC-Plus group however the VERSE treatment is prescribed by an Intervention Protocol 
provided only to the trained VERSE therapists and is designed for all aphasia types and severity 
levels.  
Therapists complete a daily therapy log in an electronic Case Report Form (eCRF) REDCap[7] for 
each participant including content, duration and frequency of all therapy sessions. UC-Plus and 
VERSE sessions will be video recorded, monitored and cross-referenced with information 
provided in the eCRF.  Deviations from the VERSE protocol will be addressed with the clinician.  
 Required study assessments and the assessment timeline are outlined in Table 2.   
All outcome assessments will be carried out by qualified and study trained speech pathologists 
who are independent blinded assessors. Information relating to resource utilisation will be 
obtained from the participant.  
Participants will be assessed for adverse events (AEs) throughout this trial. All AEs reported 
during the intervention period (between consent and 50 days post stroke), will be reported. 
AEs that relate to the new diagnosis or worsening of clinical depression will be reported up to 
week 26.   
AEs that meet the criteria for serious,(SAEs)  will be reported for the duration of the project. 
Trial therapists and blinded assessors staff will identify and report events and reviewed by a 
medical monitor and independent Data Safety Monitoring Committee. 
 
Primary Outcome 
The primary outcome is the AQ score of the WAB assessed by a blinded assessor at 12 weeks 
post stroke. The WAB is considered a reliable measure of severity of language impairment and 
is sensitive to change [6].  
 
Secondary Outcomes 
These are assessed by a blinded assessor and include; 
Health related Quality of life as determined by SAQoL- 39[10] at 12 and 26 weeks 
Resource Utilisation at 26 weeks. Participant provided services will be collected at 12 and 26 
weeks by the blinded assessor. Information will be used to estimate the cost effectiveness of 
VERSE therapy compared to UC and UC-plus. Amount and type of inpatient and outpatient 
rehabilitation, length of acute hospital stay, discharge destination, hospital readmissions, 
general practitioner visits, community and health care service use, medication use, respite and 
informal care services and any speech and communication aids/devices changes in employment 
status and services utilised as a result of the stroke will be collected. 
 
Sample Size 
A sample of 246 participants will provide 80% power to detect this difference at a (two-tailed) 
significance level of α = 0.05, after adjusting for 5% non-adherence and a loss to analysis of 12% 
(due to death and dropout).  
 
Statistical Analysis 
An intention-to-treat analysis will be used. A secondary per protocol analysis will explore dose 
related differences in the primary outcome.  
 
Primary analysis 
This will be a between-group comparison of recovery on AQ at 12 weeks. A generalized 
estimating equations model will be developed to analyse difference in recovery between 
groups. Differences in baseline AQ scores and baseline National Institute of Health Stroke Scale 
 (NIHSS)[8] will be included as covariates in the model. The intervention effect will be 
represented as the difference in percent of maximal potential recovery achieved.  
Secondary analyses  
The generalised estimating equations model developed for the primary analysis will also 
examine differences in recovery on AQ between the three groups (VERSE, UC-plus and UC) and 
to assess whether these differences are sustained at 26 weeks. 
A generalized estimating equations model will be developed to analyse differences between 
the three groups (VERSE, UC-Plus and UC) in recovery of connected speech (Discourse 
measures) at 12 weeks and 26 weeks. Baseline AQ scores and baseline modified Rankin 
Score[9], will be controlled for by including these as covariates in the model. The intervention 
effect will be represented as the difference in amount of connected speech. 
A generalized estimating equations model will be used to determine the effect of intervention 
group on Stroke and Aphasia Quality of Life Scale-39 (SAQOL-39)[10] scores at 12 and 26 weeks 
post-stroke, adjusting for known confounding variables (e.g. age, gender, NIHSS[8], mRS[9]).  
Resource utilisation will be captured using a standardised approach from a societal perspective 
with the main focus on the health sector. This will include out-of-pocket costs to patients and 
family members and workforce impacts. Incremental cost-effectiveness ratios will be reported 
as costs per unit improvement in AQ-score and per occurrence of depression (medically 
diagnosed and treated and/or an ADRS score of 9 and above) avoided at 26 weeks post stroke. 
Societal perspective costs will include government as third party payer, costs to patients and 
carers/family members and limited costs to other sectors. Probabilistic multivariable analysis 
will be conducted to account for variability around the point estimates and results will be 
reported as medians (95% uncertainty intervals) using @RISK software (Palisade 
Corporation)[11].  
 
Discussion  
This trial is designed to test whether the intensive and prescribed VERSE intervention is 
effective in promoting maximum recovery and preventing costly health complications in a 
vulnerable population of survivors of stroke. It will also provide novel, prospective, aphasia 
specific cost-effectiveness data which may be used to improve resource allocation and policy 
development in acute and subacute hospital settings for very early aphasia intervention. Since 
the trial commenced recruitment, 81 patients have been enrolled from 11 hospitals. 
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Figure 1  
CONSORT Flow diagram of the VERSE trial.      
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 Table 1. Eligibility criteria 
 
 
Inclusion criteria 
 
Patients over the age of 18 with acute stroke and resultant acute aphasia of any type (ICD- 
    10 codes 161 – 164 i.e. no TIA, SAH or SDH) 
A score  of less than  93.7 of the Aphasia Quotient  
Patients who are deemed medically stable at recruitment  
Patients with the ability to maintain a wakeful alert state for 30 consecutive minutes within 
   14 days of stroke onset  
Patients with normal or corrected hearing and vision  
Patients with informed consent obtained by participant or person responsible 
 
Exclusion criteria 
Patients will be excluded from the study if they have any of the following: 
Pre existing aphasia at the time of enrolment 
Patients who have suffered a head injury, have had or require neurosurgery. (Clot retrieval 
     surgery is not an exclusion if patient is stable post operatively and meets the above 
     criteria)  
Pre existing clinical diagnosis of dementia  
Clinical diagnosis or treatment of major depression at time of enrolment 
Concurrent progressive neurological disorders 
Patients unable to participate in English based therapy due to English being a second 
    language.   
Participation in other intervention trials without prior approval from VERSE trial manager.  
 
 
 
 
  
 Table 2. Schedule of assessment 
 
 
 
Assessment Baseline Treatment  Follow up post stroke 
 Between Day 2 
and Day 14 post 
stroke 
Day after 
Baseline (4-5 
weeks) 
Week 12  
12 weeks (+/- 7 days) 
Week 26  
26 weeks (+/- 7 days) 
Screening/Eligibility X1    
Frenchay Aphasia Screening test 
(FAST) [12] 
X1    
Consent X1    
Western Aphasia Battery (AQ)[6] X2  X5 X5# 
Randomisation X1    
Demographics X1    
Past medical History X1    
NIHSS[8] X1    
mRS[9] X1    
RBHOMB[13] X1    
Oxfordshire Classification  
(OCSP)[14] 
X1    
Clock Drawing/Cog test[10] X1    
Boston Naming Test (BNT)[15] X2  X5# X5# 
Discourse collection[16]  X2  X5# X5# 
Intervention and recording of 
therapy  
 X3 or 4   
Stroke and Aphasia Quality of life 
Scale (SAQoL-39)[10] 
  X5# X5# 
Aphasia Depression Rating Scale 
[17] 
  X5# X5# 
Resource Utilisation   X5 X5 
Patient diary provided  X3 or 4** X5  
Adverse Events   X3 X5 X5 
Serious Adverse Events  X3 X5 X5 
X1 = person screening and enrolling the subject. May be X2 
X2 = Trained speech pathologist 
X3 = Usual care speech pathologist (UC and UC Plus) 
X4 = VERSE therapist 
X5= Blinded Assessor 
** Diary provided on last day of therapy with treating speech pathologist. This may be on discharge from the acute 
ward or as late as Day 50. 
# Secondary outcome measure 
  
 
 
 
